Enzyme-responsive biomimetic solid lipid nanoparticles for antibiotic delivery against hyaluronidase-secreting bacteria

Nanotechnology Applications in Sepsis: Essential Knowledge for Clinicians

“…Recently, the novel formulations of antimicrobial-loaded particles emerged, with Mohammed et al describing an enzyme-responsive biomimetic solid lipid nanoparticle delivery system [ 54 ]. This study was directed at hyaluronidase-secreting bacteria.…”

“…Besides bacterial hyaluronidase, bacterial lipase is another known bacterial virulence factor, which triggers cell rupture and manipulates the host’s immune system by inhibiting bacterial phagocytosis [ 56 ]. In this report, Mohammed et al evaluated the efficacy of ascorbyl stearate (a vitamin C derivate and potent bacterial hyaluronidase inhibitor) as an adjuvant of a vancomycin tween-80-based lipid nanoparticle delivery system [ 54 ]. The addition of ascorbyl stearate was thought to confer both biomimetic and stimuli-responsive properties to the design and enhance its activity against S. aureus and methicillin-resistant S. aureus .…”

“…Additionally, it enhanced vancomycin’s bactericide kinetics and allowed for a significant death percentage of treated biofilms. The study by Mohammed et al showed that the vancomycin–ascorbyl stearate–lipid nanoparticle system has superior antibiotic delivery capabilities, antibacterial activity, and great potential to improve sepsis treatment outcomes [ 54 ].…”

Introducing HaNTr – Halloysite Nanotubes Targeting System for The Selective Delivery of Antibiotics

“…[ 4,8–10 ] These challenges call for the development of more specific antibiotic solutions, [ 7 ] including the option of targeted antibiotic delivery to the infecting pathogen. [ 11,12 ] Indeed, much effort has been invested in the design of such systems, utilizing various carriers, including liposomes, [ 13–15 ] solid lipid particles, [ 16 ] porous silica, [ 12,17,18 ] porous silicon, [ 19,20 ] polymeric particles, [ 21,22 ] and zeolites, [ 23 ] characterized by a wide range of loaded content (0.004 – 25 wt%) [ 12,16 ] (for a detailed description of these carriers see Table S1 in the Supporting Information). Bacterial targeting is achieved by modification of such carriers with various capture probes, such as antibiotic residues, [ 17,18 ] aptamers, [ 12,22 ] peptides, [ 19 ] and antibodies (Abs), [ 15,21 ] enabling capture of target bacteria cells, thus enhancing the antibacterial efficacy by 2‐ to 4‐fold in comparison to the antibiotic alone.…”

“…Bacterial targeting is achieved by modification of such carriers with various capture probes, such as antibiotic residues, [ 17,18 ] aptamers, [ 12,22 ] peptides, [ 19 ] and antibodies (Abs), [ 15,21 ] enabling capture of target bacteria cells, thus enhancing the antibacterial efficacy by 2‐ to 4‐fold in comparison to the antibiotic alone. [ 14,16,17,21–23 ] However, these synthetic carriers are mostly fabricated through complex processes. Moreover, their effect on non‐target bacteria and the exerted collateral disruption of the commensal human microbiome have yet to be addressed.…”